Lionel Bosquée
67 works · 1,621 citations · h-index 20
Top works
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- 83 Phase II study of docetaxel (Taxotere®) in locally advanced or metastatic non-small cell lung cancer (NSCLC): Interim report on 204 patients
- A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)
- Increased IL-6 and TGF-β1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy
- European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
- Diagnostic Performance of Soluble Mesothelin and Megakaryocyte Potentiating Factor in Mesothelioma
- Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
- Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine
- Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation
- START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
- A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
- Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms
- Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer
- Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice
- The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor
- An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
- Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
- Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer – EORTC 08062
- The Importance of Accurate Lymph Node Staging in Early and Locally Advanced Non-small Cell Lung Cancer: An Update on Available Techniques